Biweekly TAS-102 with Bevacizumab combination study - BiTS study

PO Epidemiological and Clinical Research Information Network(ECRIN)0 个研究点目标入组 46 人开始时间: 2017年9月28日最近更新: 2023年10月17日

试验速览

暂无简介。

•1. any of the following complication: a. synchronous active malignancies other than carcinoma in situ or mucosal cancer b. central nervous system metastases c. active infection d. uncontrolled ascites, pleural effusion, pericardial effusion e. bowel obstruction, renal failure, liver failure, effusion f. uncontrolled DM g. uncontrolled hypertension h. symptomatic heart disease within 12 months i. active gastrointestinal bleeding j. uncontrolled HIV infection, HBV infection, HCV infection k. immunodeficency l. sever mental disorder 2. any of the following treatment: a. thoracotomy, or intestinal resection within 4 weeks b. chemotherapy within 1 week c. extensive radiotherapy d. investigational new drug within 1 week 3. history of TAS-102 4. grade 2 or more adverse events not recovered 5. transfusion within 7 days 6. urine dipstick for proteinuria more than +2 7. severe thrombosis or severe pulmonary disease 8. unhealed wound 9. hemorrhagic diathesis 10. pregnant and lactating females 11. patients judged by the investigator as unfit to be enrolled in the study

发起方

PO Epidemiological and Clinical Research Information Network(ECRIN)